I maintain my Sell rating on Humacyte due to slow SYMVESS adoption, missed Q2 estimates, and ongoing operational challenges. SYMVESS's limited market, negative publicity, and CMS reimbursement hurdles highlight significant barriers to broader commercial success. In my opinion, HUMA's cash runway extends only into early 2026, with ongoing dilution and a likely need for additional financing soon.

SAN FRANCISCO, Aug. 12, 2025 (GLOBE NEWSWIRE) -- On August 5, 2025, investors in Marex Group plc (NASDAQ: MRX) saw the price of their shares significantly decline in the wake of a critical short report accusing the company of engaging in an improper multi-year accounting scheme. The report has triggered national shareholders rights firm Hagens Berman to commence an investigation into whether Marex may have violated the securities laws.

SAN FRANCISCO, Aug. 12, 2025 (GLOBE NEWSWIRE) -- On July 22, 2025, investors in Nutex Health Inc. (NASDAQ: NUTX) saw the price of their shares significantly fall after activist investment firm Blue Orca Capital published a critical report about Nutex and its involvement with independent dispute resolution (“IDR”) vendor HaloMD.

On Holding AG (NYSE:ONON ) Q2 2025 Earnings Conference Call August 12, 2025 8:00 AM ET Company Participants David Allemann - Co-Founder & Executive Co-Chairman Liv Radlinger - Corporate Participant Martin Hoffmann - CEO & CFO Conference Call Participants Anna A. Andreeva - Piper Sandler & Co., Research Division Aubrey Leland Tianello - BNP Paribas Exane, Research Division Cristina Fernández - Telsey Advisory Group LLC Jay Daniel Sole - UBS Investment Bank, Research Division John David Kernan - TD Cowen, Research Division Michael Charles Binetti - Evercore ISI Institutional Equities, Research Division Operator Thank you for standing by.

HIMS leverages its consumer-first telehealth model, AI-driven personalization and global expansion plans to outpace industry growth.

DE Q3 profit is likely to have dropped 26.6% on weaker demand, though price gains may have helped offset rising costs.

VCTR reports that July AUM edged up to $299.8 billion, with gains in U.S. mid-cap, large-cap, and global equities offsetting small-cap declines.

SAN FRANCISCO, Aug. 12, 2025 (GLOBE NEWSWIRE) -- On July 23, 2025, investors in Telix Pharmaceuticals Limited (NASDAQ: TLX) saw the price of their American Depositary Shares significantly fall after the company revealed that it received a subpoena from the SEC.

Key Points in This Article: Archer Aviation‘s (ACHR) Q2 earnings showed a $206 million net loss, prompting an initial stock sell-off, but shares are rising 5% as investors recognized progress.

The tiny start-up hopes to take advantage of an upcoming antitrust ruling against the tech giant.

Globant and NetEase stand out in the Internet-Software & Services industry with global reach, AI-driven growth, and resilient subscription models.

RGTI is betting on chiplet-based quantum systems to meet DARPA's benchmarks and secure a spot in its next program phase.

AB's July AUM remained unchanged sequentially at $829B, as equity gains and alternatives growth were offset by institutional outflows.

Smucker (SJM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

American technology stalwart Apple NASDAQ: AAPL just made headlines, with President Trump's influence and decision-making playing a key role in the stock's story. Below, we'll detail two key pieces of news and explain why they are leading Apple shares higher.

NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of KBR, Inc. (NYSE: KBR) resulting from allegations that KBR may have issued materially misleading business information to the investing public.

Nano-X Imaging Ltd. (NASDAQ:NNOX ) Q2 2025 Earnings Conference Call August 12, 2025 8:30 AM ET Company Participants Erez I.

Transaction in Own Shares 12 August, 2025 • • • • • • • • • • • • • • • • Shell plc (the ‘Company') announces that on 12 August, 2025 it purchased the following number of Shares for cancellation. Aggregated information on Shares purchased according to trading venue: Date of purchase Number of Shares purchased Highest price paid Lowest price paid Volume weighted average price paid per share Venue Currency 12/08/2025 347,351 £26.7800 £26.4900 £26.6045 LSE GBP 12/08/2025 186,945 £26.7700 £26.4900 £26.5950 Chi-X (CXE) GBP 12/08/2025 165,092 £26.7800 £26.4900 £26.6010 BATS (BXE) GBP 12/08/2025 342,202 €31.1350 €30.8600 …

The Estee Lauder Companies' fiscal fourth-quarter results are likely to reflect a decline due to challenges in China, travel retail and rising expenses.

CLSK shares plunge 8% despite fiscal third-quarter earnings swinging to profit and revenue surging nearly 91% year over year.